X-Linked Protoporphyria (XLP) research hub
5 indexed studies · 1 currently recruiting
- authorisedTherapeutic confirmatory (Phase III)
HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP).
This study is looking at a new medicine called Bitopertin for people with rare conditions called Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP). It aims to check if the medicine is safe, if people can tolerate it well, and if it helps them spend more time in sunlight without pain.
Italy · France · Ireland - ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients with Erythropoietic Protoporphyria (EPP).
This study is looking at a medicine called SCENESSE to see how it moves through the body of adults with a rare skin condition called EPP. It aims to understand how much of the medicine stays in the body and for how long after treatment.
Belgium · Netherlands - recruiting
Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP)
This study looks at how Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP) affect people aged 12 and over. It's an observational study, meaning you won't get new treatments, but researchers will collect information about your condition over 6 months.
United States · Belgium · Canada - active not recruitingPHASE3
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
This study is looking into a new medication called bitopertin for people with EPP or XLP. Researchers want to see if it's safe and helps people spend more time in the sun without pain, and how it affects certain blood chemicals.
United States · Australia · Belgium - active not recruitingPHASE3
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
This study is looking into a new medication called Dersimelagon for people aged 12-75 with rare conditions called EPP or XLP. It aims to see if the medication can help them spend more time in the sun without experiencing painful symptoms like burning or tingling.
United States · Australia · Bulgaria